SPRY at a glance
ARS Pharmaceuticals, Inc. (SPRY, SEC CIK 1671858) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ARS Pharmaceuticals, Inc. (SPRY) shares worth $87.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $84.3M
- −5.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $87.6M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $37.7M, up $5.2M YoY from $32.5M, driven by higher global neffy unit sales
- Net loss $35.6M vs $51.2M YoY; operating loss $34.2M vs $53.2M
- Best performer: U.S. neffy product revenue $33.4M vs $31.3M; supply revenue $2.6M vs $1.1M
- Cash, equivalents and short-term investments $138.4M; operating cash use $139.6M for nine months vs $127.4M
- Outlook: resources expected sufficient until cash-flow breakeven; Phase 2b ARS-2 interim data expected first quarter 2027
Risk Factors
- Newly added trade risk: EU-sourced materials face potential pharmaceutical tariffs, with alternative qualification requiring 18-24 months
- Regulatory risk: Cipla filed paragraph IV challenges in March 2026, prompting ARS to sue in April 2026
- Commercial risk: Competitor Anaphylm’s NDA resubmission received FDA review, with a March 2027 target action date
- Financial risk: $125.0 million Credit Agreement balance, plus a $25.0 million minimum liquidity covenant
- Liquidity risk: Net loss $158.5 million and accumulated deficit $453.1 million as of September 30, 2026
AI summary of the SPRY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Detailed revenue, profitability, cash position and operating updates in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $37.7M, up from $32.5M, with neffy U.S. product revenue $33.4M
- U.S. neffy market share reached 5%, while field-targeted accounts reached 9% versus 2% in non-targeted accounts
Item EX-99.1: Item EX-99.1
- Q2 revenue $33.7M, including $26.2M neffy product revenue versus $12.8M in Q2 2025
- U.S. neffy market share reached 5%, while field-targeted accounts reached 8% versus 4% in Q2 2025
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed earnings release and financial performance information
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Richard Lowenthal resigned from the Board effective July 15, 2026, tied to severance eligibility
- Chief Medical Officer Sarina Tanimoto terminated without cause on July 15, 2026
AI summaries of SPRY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SPRY
Don't miss the next SPRY filing
- Alerts as it files. A push when SPRY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SPRY, by share count.
- Ask anything. An AI agent that reads every SPRY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Slebir John L | A | Nov 2, 2026 | 1,199,482 | - |
| Casale Donn | A | Oct 1, 2026 | 1,036,923 | - |
| Smith Margaret Ekins | A | Sep 1, 2026 | 1,001,738 | - |
| Casale Donn | A | Jul 1, 2026 | 898,456 | - |
| Shah Pratik | A | Jun 24, 2026 | 30,000 | - |
| SCHNEIDER PHILLIP M | A | Jun 24, 2026 | 30,000 | - |
| Shawver Laura | A | Jun 24, 2026 | 30,000 | - |
| Kelly Michael | A | Jun 24, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $89.1M | $84.3M |
| Operating Income | - | -$3.1M | -$179.4M |
| Net Income | -$54.4M | $8.0M | -$171.3M |
| Op. Margin | - | -3.5% | -212.9% |
| Net Margin | - | 9.0% | -203.3% |
| Balance Sheet | |||
| Total Assets | $233.2M | $351.2M | $327.7M |
| Equity | - | $256.8M | $114.3M |
| ROE | - | 3.1% | -149.9% |
| Per Share | |||
| EPS | $-0.57 | $0.08 | $-1.74 |
| Cash Flow | |||
| Operating CF | - | $13.5M | -$170.9M |
| CapEx | $175K | $563K | $339K |
Source: XBRL data in ARS Pharmaceuticals, Inc. (SPRY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SPRY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $87.6M |
| Q2 2026 | 27 | $155.9M |
| Q1 2026 | 26 | $219.6M |
| Q4 2025 | 23 | $256.0M |
| Q3 2025 | 23 | $205.6M |
| Q2 2025 | 25 | $365.2M |
| Q1 2025 | 23 | $170.8M |
| Q4 2024 | 18 | $137.6M |
- Millennium Management+869.1K (+36%)
- Citadel Advisors LLC+547.8K (+103%)
- BlackRock+270.5K (+5%)
- Morgan Stanley+145.6K (+64%)
- AQR Capital Management+61.7K (+173%)
- JPMorgan Chase & Co−323.5K (-89%)
- Bank of America Corp−163.2K (-35%)
- Goldman Sachs Group−56.1K (-15%)
- Vanguard Capital Management LLC−51.6K (-2%)
- State Street Corp−42.0K (-1%)
- Renaissance Technologies LLC+174.2K
- StoneX Group Inc.+10.2K
- M&T Bank+11.8K
- FMR LLC (Fidelity)−349.2K
- Dimensional Fund Advisors−115.5K
- Principal Financial Group−29.7K
- Allstate−29.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SPRY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 15, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SPRY SEC filings: frequently asked questions
Which institutions hold SPRY stock?
As of September 30, 2026, the largest ARS Pharmaceuticals, Inc. (SPRY) holders among the 13F filers tracked by SignalX were BlackRock ($24.1 million), State Street Corp ($15.9 million), Millennium Management ($14.1 million), Vanguard Capital Management LLC ($10.8 million), Citadel Advisors LLC ($4.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SPRY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.
What did SPRY report in its latest 8-K?
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.
What are the latest SPRY SEC filings?
ARS Pharmaceuticals, Inc. (SPRY) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 4, 2026.
What is SPRY's SEC CIK number?
ARS Pharmaceuticals, Inc. (SPRY)'s SEC Central Index Key (CIK) is 1671858. EDGAR lists every SPRY filing under that number.
Ask anything about SPRY
The research agent reads SPRY's filings, financials, insider trades and 13F holders, then answers with sources.